Chinese biopharmaceutical company Yisheng Biopharma has completed its Phase I clinical trial of PIKA hepatitis B vaccine to provide prophylactic and therapeutic benefits against hepatitis B virus infection.
The vaccine uses toll-like receptor-3 (TLR-3) agonist technology platform PIKA adjuvant technology, which has been designed to deliver toll-like receptor-3 (TLR-3) agonist molecules to activate the innate immune cells such as dendritic cells, macrophages and NK cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PIKA adjuvant has been formulated as a component of PIKA adjuvant-based hepatitis vaccine. The PIKA adjuvant platform has also exhibited a safety profile while tried in multiple clinical trials of Yisheng's rabies vaccine.
The Phase I clinical study is being conducted as a randomised, double blind, active-controlled, dose escalation study conducted at the Singapore General Hospital (SGH) and Changi General Hospital (CGH) in Singapore to test the safety, tolerability and immunogenicity of the investigational PIKA hepatitis B vaccine.
The trial enrolled 32 healthy volunteers and results suggested safety and tolerability of the hepatitis B vaccine.
Overseeing the clinical programme in Singapore, Dr Zhongkai Shi said: "PIKA's potent anti-viral and robust immune-stimulating capability makes PIKA platform well suited for the development of both preventive and therapeutic vaccine against the hepatitis B virus.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Such encouraging data is setting up a good foundation to initiate a Phase II clinical study with an expanded study population and to further evaluate the clinical safety, immunogenicity and efficacy of the investigational vaccine.”
